Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 8;49(4):985-992.
doi: 10.3906/sag-1809-36.

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

Müfide Okay  1 , Yahya Büyükaşık  1 , Haluk Demiroğlu  1 , Ümit Yavuz Malkan  2 , Rafiye Çiftçiler  1 , Elifcan Aladağ  1 , Salih Aksu  1 , İbrahim Celallettin Haznedaroğlu  1 , Nilgün Sayınalp  1 , Osman İlhami Özcebe  1 , Hakan Göker  1
Affiliations

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

Müfide Okay et al. Turk J Med Sci. .

Abstract

Background/aim: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma.

Materials and methods: The study group included 53 patients who were relapsed/refractory HL (n = 14) and NHL (n = 39) and received mitoxantrone and melphalan followed by ASCT. The transplant regimen consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) followed by peripheral blood stem cell infusion (PBSC).

Results: Prior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were in partial remission (PR), and 17% had stable or progressive disease. After high-dose chemotherapy and PBSC, 44 out of 51 patients achieved CR (86.2%). CR was achieved in 24 out of 33 patients (72.7%) who were transplanted in a marginally active phase of the disease. At a median followup of 25.4 months (1.8–131.3 months) after ASCT, 13 patients relapsed/ progressed and 8 patients died. The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was 59.3%.

Conclusion: High-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractory lymphoma patients who are undergoing ASCT.

Keywords: Lymphoma; relapsed; autologous stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST:

none declared

Figures

Figure 1
Figure 1
The 5-year OS, DFS, and EFS projections of the patients.
Figure 2
Figure 2
The OS, DFS, EFS durations of the patients according to the pretransplant evaluations.
See this image and copyright information in PMC

References

    1. Linch D Goldstone A McMillan A Chopra R Hudson GV Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. The Lancet. 1993;341:1051. - PubMed
    1. Stiff PJ Unger JM Cook JR Constine LS Couban S Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. New England Journal of Medicine. 2013;369:1681. - PMC - PubMed
    1. Philip T Guglielmi C Hagenbeek A Somers R Van der Lelie H Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New England Journal of Medicine. 1995;333:1540. - PubMed
    1. Mills W Chopra R McMillan A Pearce R Linch D BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. Journal of Clinical Oncology. 1995;13:588. - PubMed
    1. Chen Y-B Lane AA Logan BR Zhu X Akpek G Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2015;21:1046. - PMC - PubMed